Growth hormone-releasing hormone analog
CJC-1295 (no DAC)
Often marketed as modified GRF(1-29)
Not FDA-approvedA short-acting growth hormone-releasing hormone analog sold under inconsistent research-market naming. “CJC-1295 without DAC” is often used for modified GRF(1-29), which should not be assumed equivalent to long-acting CJC-1295 with a drug-affinity complex.
FULL RESEARCH GRAPHIC
CJC-1295 (no DAC) research overview
A phone-readable overview of the proposed signaling pathway, evidence limits, marketed claims, and known safety concerns.
Tap the graphic to open the full-resolution version.
RESEARCH SIGNAL MAP
04 ACTIVE FIELDSEVIDENCE READOUT
Not FDA-approvedPublished human CJC-1295 studies commonly evaluated the long-acting DAC form. Those findings do not establish the identity, safety, dose, or effectiveness of a product marketed as “CJC-1295 without DAC.”
BOUNDARY CHECK
CONTEXT REQUIREDFDA identifies compounded CJC-1295 as presenting potential immunogenicity and peptide-impurity concerns, with limited clinical data and reports of serious adverse events.
SUBMITTED LAB DOCUMENTS
Test results
Reports may describe other strengths or blends. Match the labeled amount, composition, and exact lot to your vial. A report for another strength does not verify your vial. Each record identifies whether an exact lot was supplied.
VIAL REFERENCE
3 mL mixing math & dosing context
Every number is labeled by evidence level. The 3 mL reference calculates concentration and U-100 volume; it does not prove solvent compatibility, sterility, stability, or suitability for injection.
10 mg vial
Change the liquid. See the amount.
Calculation only: vial amount ÷ liquid volume × draw volume. It does not determine what dose to use or confirm product compatibility.
3.0 mL BAC-water workflow
- First confirm that bacteriostatic water and a 3.0 mL final volume are compatible with the exact product and vial capacity.
- Clean both vial stoppers with alcohol and allow them to dry.
- Add the 3.0 mL slowly down the inside wall instead of directing pressure onto the powder.
- Gently roll or swirl until dissolved; do not shake.
- Use product-specific refrigeration and discard guidance. If none exists, do not invent a beyond-use date.
No controlled dose for the no-DAC product
Published human CJC-1295 dose-escalation studies evaluated the long-acting DAC form. Those data do not establish the identity, dose, frequency, or safety of short-acting modified GRF(1-29) sold as CJC-1295 without DAC.
FDA — compounding safety risks ↗U-100 means 100 units = 1.0 mL. Any table result above 100 units exceeds one standard 1 mL U-100 syringe.